UNICREDIT BANK/CALL/ELI LILLY & CO/1100/0.1/18.12.24 | Market Closed - BOERSE MUENCHEN 20:41:23 24/05/2024 BST | ||
| 1.38 EUR | 0.00% |
|
| Current month | +23.21% | ||
| 1 month | +74.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 1.38 | 0.00% |
| 23/05/24 | 1.38 | +10.40% |
| 22/05/24 | 1.25 | +5.04% |
| 21/05/24 | 1.19 | +22.68% |
| 20/05/24 | 0.97 | +12.79% |
Real-time BOERSE MUENCHEN
Last update May 24, 2024 at 08:41 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD3BKN |
| ISIN | DE000HD3BKN1 |
| Date issued | 04/03/2024 |
| Strike | 1,100 $ |
| Maturity | 18/12/2024 (208 Days) |
| Parity | 10 : 1 |
| Emission price | 1.78 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.12 € |
|---|---|
| Lowest since issue | 0.64 € |
| Spread | 0.04 € |
| Spread % | 2.90% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.37%
- Stock Market
- Warrants
- Warrant
